Literature DB >> 14718627

Protection against wild-type murine gammaherpesvirus-68 latency by a latency-deficient mutant.

Jessica M Boname1, Heather M Coleman1, Janet S May1, Philip G Stevenson1.   

Abstract

A murine gammaherpesvirus-68 (MHV-68) mutant with deregulated transcription of its ORF50 transactivator was severely impaired in latency establishment. The deregulated virus showed reduced immunogenicity, probably reflecting a lower antigen load. However, it still elicited effective immunity to a subsequent wild-type (WT) virus challenge. Infection was not completely prevented, but was very substantially reduced in extent and the long-term level of WT viral DNA in lungs and spleens remained low. Thus latency-deficient MHV-68 illustrates a possible general approach to creating attenuated gammaherpesvirus vaccines that can protect against pathogenic WT infections.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14718627     DOI: 10.1099/vir.0.19592-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Dendritic cells loaded with tumor B cells elicit broad immunity against murine gammaherpesvirus 68 but fail to prevent long-term latency.

Authors:  Janet Weslow-Schmidt; Fang Ye; Stephanie S Cush; Kathleen A Stuller; Marcia A Blackman; Emilio Flaño
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Importance of antibody in virus infection and vaccine-mediated protection by a latency-deficient recombinant murine γ-herpesvirus-68.

Authors:  Michael L Freeman; Claire E Burkum; David L Woodland; Ren Sun; Ting-Ting Wu; Marcia A Blackman
Journal:  J Immunol       Date:  2011-12-23       Impact factor: 5.422

3.  Replication and transcription activator (RTA) of murine gammaherpesvirus 68 binds to an RTA-responsive element and activates the expression of ORF18.

Authors:  Yun Hong; Jing Qi; Danyang Gong; Chuanhui Han; Hongyu Deng
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

Review 4.  Prospects of a novel vaccination strategy for human gamma-herpesviruses.

Authors:  Ting-Ting Wu; Marcia A Blackman; Ren Sun
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

5.  Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.

Authors:  Qingmei Jia; Michael L Freeman; Eric J Yager; Ian McHardy; Leming Tong; DeeAnn Martinez-Guzman; Tammy Rickabaugh; Seungmin Hwang; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

6.  Gammaherpesvirus modulation of mouse adenovirus type 1 pathogenesis.

Authors:  Yn Nguyen; Bryan A McGuffie; Victoria E Anderson; Jason B Weinberg
Journal:  Virology       Date:  2008-09-02       Impact factor: 3.616

7.  Vaccination against a hit-and-run viral cancer.

Authors:  Philip G Stevenson; Janet S May; Viv Connor; Stacey Efstathiou
Journal:  J Gen Virol       Date:  2010-06-23       Impact factor: 3.891

8.  Olfactory Entry Promotes Herpesvirus Recombination.

Authors:  Wanxiaojie Xie; Kimberley Bruce; Helen E Farrell; Philip G Stevenson
Journal:  J Virol       Date:  2021-09-15       Impact factor: 5.103

9.  Gammaherpesvirus Colonization of the Spleen Requires Lytic Replication in B Cells.

Authors:  Clara Lawler; Marta Pires de Miranda; Janet May; Orry Wyer; J Pedro Simas; Philip G Stevenson
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

10.  Gamma-herpesvirus latency requires T cell evasion during episome maintenance.

Authors:  Neil J Bennett; Janet S May; Philip G Stevenson
Journal:  PLoS Biol       Date:  2005-03-22       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.